Skip to content

A POST MARKETING SURVEILLANCE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ANTICID LIQUID

Retrospective, cross sectional and open labeled randomized clinical trial to evaluate Anticid Liquid through post marketing surveillance

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/03/050336
Enrollment
200
Registered
2023-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K259- Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation

Interventions

None listed

Sponsors

Pankajakasthuri Herbals India Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either gender in the age group between 18 -85 years 2. Patients having Symptoms of Digestive system disorders 3. Willing to enrol in study by signing Informed consent

Exclusion criteria

Exclusion criteria: 1. Earlier participation in this study 2. Patients having other systemic diseases not under control 3. Patients who are not willing to sign the informed consent form 4. Patients who are diagnosed with malignancies 5. Post-surgical cases 6. Patients with severe symptoms of acute onset 7. Unable to respond properly for questionnaire or when a patient is too severely ill to answer the questions

Design outcomes

Primary

MeasureTime frame
Any incidents of adverse events after the administration of Anticid Liquid. Any marked change in safety parameters measured during the administration of the product Reporting the effectiveness of this product in the management of GI disorders and associated complaints Timepoint: Assessment parameters will be assessed on 0th day, 15th day, 30th day, and 45th day. If symptoms subsided on 15th day, follow up assessment will be done on 30th day.

Secondary

MeasureTime frame
Additional therapeutic advantages of the productTimepoint: Assessment parameters will be assessed on 0th day, 15th day, 30th day, and 45th day. If symptoms subsided on 15th day, follow up assessment will be done on 30th day.

Countries

India

Contacts

Public ContactMr Arun Visakh Nair

Pankajakasthuri Herbal research Foundation

drshan@pkhil.com09188325339

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026